BTAI (bioxceltherapeutics.com) Future Price to Earnings

BioXcel Therapeutics Corp - graphic logo of issuer BTAI

The consensus forward P/E of BioXcel Therapeutics (BTAI) illustrates the link between psychiatric centers' demand for agitation treatments and the outsourcing of production to CDMO plants. The current level stands at 0.00, confirming the market valuation of BioXcel Therapeutics assets. Stable raw material inventories and streamlined logistics guarantee sustainable growth of indicators in the future.

BTAI - BioXcel Therapeutics Inc Projected Price to Earnings Ratio over the range 07/04/2022 - 09/19/2026

Financial and market metric breakdowns for BioXcel Therapeutics Corp (BTAI)

- current price and projected stock value:
Stock Quotes BioXcel Therapeutics, Inc.|BTAI - Fair Value Consensus
- business market valuation indicators:
Market Value BioXcel Therapeutics Inc|BTAI - Business Value
- balance sheet equity data:
Book Value per Share BioXcel Therapeutics|BTAI - Total Stockholders' Equity|Market Cap to Net Assets Ratio bioxceltherapeutics.com|BTAI - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity BioXcel Therapeutics|BTAI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity BioXcel Therapeutics|BTAI - Company Cumulative Debt|Debt to Book Capitalization Ratio BioXcel Therapeutics Inc|BTAI - Company Long-Term Debt|Company Short-Term Debt BioXcel Therapeutics|Quick Ratio bioxceltherapeutics.com
- earnings and market ratios statistics:
BTAI - Annual Net Income|Future Profit BioXcel Therapeutics|BTAI - Market Cap to Earnings|Forward P/E Multiple BioXcel|BTAI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioXcel Therapeutics Inc|BTAI - Operating income before deduction of amortization|Earnings per share for the last twelve months BioXcel Therapeutics|BTAI - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bioxceltherapeutics.com|BTAI - Earnings per share growth this year|Earnings growth forecast for next year BioXcel Therapeutics
Analysis of all company metrics:BTAI BioXcel Therapeutics, Inc.
Signature product of BioXcel Therapeutics

The forward P/E reflects the ratio of the current share price to projected earnings, allowing for an assessment of market expectations regarding the issuer's profitability for the upcoming period. By analyzing the forward P/E valuation trends of BioXcel Therapeutics (BTAI), an investor can determine the degree of the asset's overvaluation, which is critical for BioXcel Therapeutics, as its market capitalization depends on the effectiveness of implementing AI into the repurposing of psychiatric drugs.

Competing companies

Projected Price to Earnings JAZZ (Jazz Pharmaceuticals plc)|CYTK (Cytokinetics Inc.) - Future Price to Earnings Multiple|Future Price to Earnings PTC Therapeutics Corp PTCT|SRRK: Price to Future Earnings Ratio|Centessa Pharmaceuticals - Forward P/E Multiple|Projected Price to Earnings Ratio dyne-tx.com|EWTX (Edgewise Therapeutics, Inc.) - Projected Price to Earnings|Rapport Therapeutics Inc (RAPP) - Forward P/E Multiple|Future Price to Earnings Alumis Corp|ZVRA: Future Price to Earnings Multiple|Future Price to Earnings Contineum Therapeutics, Inc. (CTNM)|LRMR - Projected Price to Earnings Ratio|Future Price to Earnings Capricor Therapeutics, Inc. CAPR|Entrada Therapeutics Inc. - Future Price to Earnings|PTHS - Future Price to Earnings|Projected Price to Earnings Ratio MediciNova, Inc.|SER: Forward P/E Multiple|Forward Price to Earnings Multiple ProMIS Neurosciences, Inc. PMN|Projected Price to Earnings APUS|Projected Price to Earnings Ratio AEON Bio AEON|Forward P/E Multiple NLSP|Future Price to Earnings BNOX (bionomics.com.au)|Forward P/E Multiple HUGE (FSD Pharma)|Market Cap to Projected Earnings reatapharma.com (RETA)